Apollomics settles Cayman Islands litigation for $5 million Nov 19, 2025 05:56PM
Apollomics remains listed on NASDAQ after compliance determination Oct 15, 2025 02:37PM
NASDAQ resumes trading in Apollomics shares and warrants Oct 14, 2025 04:06PM
Apollomics (APLM) and LaunXP Announce Development and Commercialization Agreement for Vebreltinib Mar 31, 2025 08:01AM
Apollomics (APLM) Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China Dec 20, 2024 08:01AM


Nov 21, 2024 08:00AM Apollomics (APLM) Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
Aug 13, 2024 08:19AM Apollomics (APLM) Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Jul 16, 2024 04:50PM Apollomics (APLM) Granted 180-Day Extension to Regain Compliance